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The cardiorenal syndrome type 4 (Chronic Renocardiac Syndrome) is characterized by a condition of primary chronic kidney
disease(CKD)thatleadstoanimpairmentofthecardiacfunction,ventricularhypertrophy,diastolicdysfunction,and/orincreased
risk of adverse cardiovascular events. Clinically, it is very diﬃcult to distinguish between CRS type 2 (Chronic Cardiorenal
Syndrome) and CRS type 4 (Chronic Renocardiac Syndrome) because often it is not clear whether the primary cause of the
syndrome depends on the heart or the kidney. Autosomal dominant polycystic kidney disease (ADPKD), a genetic disease that
causes CKD, could be viewed as an ideal prototype of CRS type 4 because it is certain that the primary cause of cardiorenal
syndrome is the kidney disease. In this paper, we will brieﬂy review the epidemiology of ADPKD, conventional and novel
biomarkers which may be useful in following the disease process, and prevention and treatment strategies.
1.Introduction
Heart performance and kidney function are closely inter-
connected, both in healthy and in disease conditions. It is
also clear that there is a strong connection between renal
and cardiovascular diseases. This bidirectional relationship
between heart and kidney is physical, chemical, and biologi-
cal. Primary disorders of one of these two organs often result
in secondary dysfunction or injury to the other [1].
In this paper, we discuss about the ADPKD and its
relationwithcardiorenalsyndrome.“Cardiorenalsyndrome”
(CRS) was deﬁned as the pathophysiological disorder of the
heart and kidney in which acute or chronic dysfunction in
one organ may induce acute or chronic dysfunction in the
other organ [2]. A large number of direct and indirect eﬀects
of each organ dysfunction can initiate and perpetuate the
combined disorder of the two organs through a complex
combination of neurohumoral feedback mechanisms [3].
For this reason, it was necessary to classify and divide the
cardiorenal syndrome into diﬀerent subtypes to provide a
moreconciseandlogicallycorrectapproachtothiscondition
(see Table 1)[ 2].
Patients with CKD are at higher risk for cardiovascular
events [4], and they have a 10- to 20-fold increased risk of
cardiac death compared with age-gender-matched control
subjects without CKD [5]. Part of this problem may be
related to the fact that such individuals are also less likely to
receive risk-modifying interventions compared to their non-
CKD counterparts [6]. The association between reduced
renalfunctionandcardiovascularriskappearstoconsistently
occur at estimated GFR levels below 60ml/min/1.73m2 [7].
Clinically, it is very diﬃcult to distinguish between CRS type
2 (Chronic Cardiorenal Syndrome) and CRS type 4 (Chronic
Renocardiac Syndrome) because often it is not clear whether
the primary cause of the syndrome depends on the heart or
the kidney.
Autosomal dominant polycystic kidney disease, a genetic
disease that causes CKD, could be viewed as an ideal
prototype of CRS type 4 because it is certain that the kidney
disease is the primary process. In this paper, we will brieﬂy2 International Journal of Nephrology
Table 1: Classiﬁcation of cardiorenal syndorme (CRS).
Acute cardiorenal syndrome CRS type 1 Abrupt worsening of cardiac function leading to acute kidney injury
(AKI)
Chronic cardiorenal syndrome CRS type 2 Chronic abnormalities in cardiac function causing progressive
chronic kidney disease (CKD)
Acute renocardiac syndrome CRS type 3 Sudden worsening of renal function causing acute cardiac
dysfunction
Chronic renocardiac syndrome CRS type 4
Condition of primary CKD leading to an impairment of the cardiac
function (ventricular hypertrophy, diastolic dysfunction) and/or
increased risk of adverse cardiovascular events.
Secondary cardiorenal syndrome CRS type 5 Systemic disorders (e.g., sepsis) causing both cardiac and renal
dysfunction
review the epidemiology of ADPKD, conventional and novel
biomarkers which may be useful in following the disease
process, and prevention and treatment strategies.
2. Deﬁnition, Classiﬁcation, andEpidemiology
ADPKD occurs worldwide and in all races and ethnic groups
[8]. It accounts for ∼10% of patients on renal replacement
therapy representing an important cause of end-stage renal
disease (ESRD) worldwide [9]. Prevalence of the disease is
higher than that of Huntington disease, hemophilia, sickle
cell disease, cystic ﬁbrosis, myotonic dystrophy, and Down
syndrome combined, and it occurs in approximately 1 of
every 400 to 1000 live births [10]. Epidemiological data on
the prevalence of ADPKD have been extensively reported,
mainlyintheUnitedStatesandEurope.ADPKDisthefourth
leading cause of CKD in the United States accounting for
approximately 3% of cases [11]. In Europe, ADPKD as etiol-
ogy of CKD Stage V has been reported as 7.8 and 6.0 per mil-
lion for men and women, respectively [12]. With the advent
of renal replacement therapy, cardiovascular complications
have emerged as the major cause of death in ADPKD [13].
ADPKD is a genetically heterogeneous disease identi-
ﬁed by two phenotypically similar forms associated with
several mutations in two genes: the PKD1 gene located on
chromosome 16 (16p13.3) and the PKD2 gene mapped to
chromosome 4 (4q13–q23) [14]. A variety of genetic defects
havebeendescribedinADPKDpatients,includingdeletions,
frameshift, and missense mutations. Mutations of PKD1
gene, encoding the polycystin-1 protein, result in ADPKD
type I (ADPKD1) which is responsible for approximately
85% of ADPKD cases. Gene PKD2 mutations, encoding the
polycystin-2 protein, result in ADPKD type II (ADPKD2),
corresponding to 15% of ADPKD cases [15].
Polycystin-1 is a large integral membrane protein with
a domain architecture suggesting a function in cell-cell
or cell-matrix interaction [16]. Polycystin-2 is a member
of the calcium-permeable subfamily of transient receptor
potential channels and forms a complex with polycystin-1
[17]. Polycystins are expressed in vascular smooth muscle
and endothelia; it suggests a direct role of these proteins
in the vascular manifestations of ADPKD [18, 19]. Both
polycystin-1 and polycystin-2 are present in the primary
cilium of tubular epithelial cells [20]. Mutations in these
genes lead to abnormalities in cell proliferation, apoptosis,
tubular basement membranes, and tubular ﬂuid secretion,
ultimately resulting in slowly expanding renal cysts [21].
The precise processes leading to cyst formation and loss
of renal function remain incompletely understood. Several
mechanisms contributing to the cyst formation have been
identiﬁed, including a imbalance between epithelial cell
proliferation and apoptosis, secretor defects, altered cell–
matrix interactions, cell polarity, ciliary dysfunction, and
altered intracellular signaling [22].
2.1. Clinical Presentation. Clinically, ADPKD is an adult-
onset disease characterized by progressive, bilateral renal
cyst development and expansion of the kidneys [23]. Many
patients with ADPKD are completely asymptomatic and
often are diagnosed because of their positive family history
or the development of hypertension (HP) [21]. Whether
ADPKD2 patients are compared to ADPKD1, they seem to
have a milder clinical presentation. Cysts and kidney failure
occur at an earlier age in ADPKD1; the average age of CKD
stage V is approximately 57years in type I versus 69years
in type II [24]. ADPKD is a disease with a variable clinical
coursenotonlyamongfamilieswithdiﬀerentmutations, but
within families with a deﬁned mutation as well; it can be
explained to the large extent by its genetic heterogeneity and
modiﬁer genes. Cysts may also develop in other organs. Liver
cysts develop in more than 80% of patients, and the cysts are
usually larger in women than in men [25]. Usually, cysts do
not aﬀect liver function. About 10% of patients have cysts in
the pancreas, but these are functionally insigniﬁcant. Other
locations of cysts include the spleen, arachnoid membranes,
and seminal vesicles in men [26].
Hypertension is probably the most remediable and
serious complication of ADPKD [10]. The new onset of
HP in a patient at risk for polycystic kidney disease should
prompt aggressive treatment and diagnostic studies. These
patients during the course of ADPKD have early and more
severe left ventricular hypertrophy (LVH). ADPKD may also
occur with abdominal, back, and ﬂank pain. Hematuria
may be present secondary to cysts rupture. Urinary tract
infections are also common.
A number of noncystic manifestations such as cardio-
vascular deﬁcits, cardiac valve abnormalities, diverticular
disease, and intracranial aneurysms are also associated withInternational Journal of Nephrology 3
ADPKD; in fact, cardiovascular complications are the major
cause of morbidity and mortality in patients with ADPKD
[13].
2.2. Cardiovascular Complications. Mitral valve prolapsed
(MVP) occurs in about 26% of aﬀected adults compared
w i t h2 %o fc o n t r o ls u b j e c t s[ 27, 28]. Aortic valve insuﬃ-
ciencycanoccurinassociationwiththeaorticroot.Although
these lesions may progress with time, they rarely need valve
replacement. Screening echocardiography is not indicated
unlessamurmurisdetectedonexamination[12].Pericardial
eﬀusion may occur with an increased frequency in patients
with ADPKD (35% versus 9% in a control group of patients
with another chronic nephropathy), possibly as a result of
increased compliance (or as a collagen protein dysfunction)
of the parietal pericardium. Nevertheless, these eﬀusions are
generally well tolerated and clinically inconsequential. It is
known that the kidney disease is strongly associated with
a greater carotid Intima-Media Thickness (IMT). Subjects
with ADPKD, even with preserved renal function, have
a greater carotid IMT compared with healthy controls;
carotid IMT is higher in hypertensive ADPKD patients
[29].
It is challenging to clearly segregate those cardiovascular
features due to the genetic disorder versus the secondary
cardiovascular consequences of declining kidney function
per se. However, recent improvement and expansion of
genetically modiﬁed ADPKD animal models which mimic
the human form are providing additional insights into the
molecular mechanisms governing these disease processes as
well as the development of cardiovascular complications.
Several studies have provided convincing evidence that
these vascular abnormalities are caused by alterations in
the arterial wall linked to mutations in PKD1 or PKD2
[30].
Heterozygous mutant PKD1 or PKD2 mice appear
normal but develop single cysts in the kidney or liver
late in life and have a reduced overall lifespan [23, 31].
Homozygous null mutant mice are embryonically lethal and
die in utero or perinatally because of systemic defects with
massively enlarged cystic kidneys, pancreatic ductal cysts,
andpulmonaryhypoplasiaandoftenexhibitedema,vascular
leaks, and rupture of blood vessels. It suggests the role
of polycystins for the structural integrity of blood vessels
[23, 31, 32].
In addition, most of the homozygous knockout embryos
display multiple cardiac abnormalities including cardiac sep-
tation defects, double outlet right ventricle, and pericardial
eﬀusions [31, 33].
Moreover, Kurbegovic et al. engineered and described a
Pkd1 transgenic mice (Pkd1(TAG) mice) that, in addition
to the cystic phenotype, developed cardiac anomalies with
severe left ventricular hypertrophy, marked aortic arch
distention, and/or valvular stenosis and calciﬁcation [34].
Therefore, the cardiovascular complications seen in
ADPKD patients begin to be recognized not only as a
consequenceofdecliningkidneyfunction,butalsoasadefect
due to the loss of polycystin-1 and/or polycystin-2 function
in cardiovascular organs [31].
2.3. Hypertension and Left Ventricular Hypertrophy. As pre-
viously mentioned, hypertension and its consequent left
ventricular hypertrophy are common in ADPKD patients,
even in young adults, compared with unaﬀected controls
[28].Moreover,HPandLVHareassociatedwithafasterpro-
gression to ESRD and an increased cardiovascular mortality
[35, 36]. It is well known that HP and LVH are associated
with an accelerated rate of renal functional deterioration
[37]. Both HP and LVH are important risk factors for
cardiovascular death, the most frequent cause of mortality in
ADPKD patients [13]; thus left ventricular hypertrophy may
be considered a powerful indicator of mortality [38].
Hypertension in ADPKD occurs before the loss of kidney
function in 60% of aﬀected individuals and increases to
almost 100% in patients with CKD stage IV-V [39, 40]. The
average age of onset of hypertension is 30–34 years [41], with
men more commonly aﬀected than women [42]. In added,
i t so c c u r r e n c ei se a r l i e ra n dm o r ec o m m o ni nA D P K D 1
than ADPKD2 patients [43]. The mechanisms leading to
hypertension in ADPKD are not well understood.
However, it is now well known that increased activity
of the intrarenal rather than the systemic renin-angiotensin
system (RAS) is responsible for many forms of hypertension.
Persistent elevation of intrarenal angiotensin II (ANG II)
production with the inability to reduce ANG II in response
to a high sodium intake will result in resetting the pressure-
natriuresis relationship towards higher blood pressures lead-
ing to hypertension [44, 45].
Hypertension is associated with larger kidney size,
reﬂecting a larger number of cysts and with the severity
of kidney disease. Hypertensive ADPKD patients with
normal kidney function show greater kidney volumes versus
age-matched normotensive ADPKD men and women [41]
increased proteinuria [46] and decreased renal blood ﬂow
[47]. Renal blood ﬂow is reduced in hypertensive ADPKD
patients versus matched essential hypertensive patients
[47], and the renal resistive indices are also increased in
hypertensive ADPKD subjects and are correlated with a loss
of kidney function [43].
Renal structural changes play an important role in
the pathogenesis of the HP, and renal arteriograms from
end-stage ADPKD-nephrectomized specimens demonstrate
marked attenuation of the vasculature due to the extrin-
sic compression by the presence of the cysts and their
replacement by the latter [48]. Renal angiographic images of
hypertensive ADPKD patients (from mild to advanced renal
failure) show a large amount of a vascular renal substance
peripheraltotheoutermostbranchesofthearterialtree[48].
Hypertensive ADPKD adults with normal kidney func-
tion show a greater frequency of LVH versus normoten-
sive ADPKD men (50% versus 30%) and women (52%
v e r s u s2 2 % )a sw e l la sw i t hh e a l t h yc o n t r o l s[ 49]. They
also show greater left ventricular mass index (LVMI) in
comparison to matched essential hypertensive population
[43, 50]. The prevalence of LVH is increased even in the
early stages of CKD, and the frequency increases progres-
sively as renal function decreases [51]. Several studies have
shownincreasedLVMI,leftventriculardiastolicdysfunction,
endothelial dysfunction, and increased carotid IMT in young4 International Journal of Nephrology
normotensive patients with ADPKD with well-preserved
renal function. These ﬁndings suggest the cardiovascular
involvement in the early stages during the course of ADPKD
[26]. In experimental studies, hypertrophy was found not
only in the left, but also in the right ventricle; these
ﬁndingsexcludethatsimplehemodynamicfactors(increased
preload and afterload) are the only explanation [51]. It is
quite important to appreciate that hypertrophic remodeling
comprises not only cardiomyocyte hypertrophy, but also
interstitial ﬁbrosis and microvessel disease [38].
2.4. Intracranial Aneurysms. A major complication of
ADPKD includes the intracranial aneurysms (ICAs); the
prevalence of ICA in patients with ADPKD ranges from 4
to 12%, compared to a prevalence of 1% for the general
population [52]. A familial clustering of ICA is found, with
a 5times greater chance of detecting an ICA in a subject
with a relative with a ruptured ICA [52, 53]; it suggests that
genetic factors may be associated with the development of
this complication [23]. This family clustering is in agreement
with the ﬁnding that patients with mutations in the 5
  region
of PKD1 are more likely to have ICA than patients with 3
 
mutations, especially in those with ICA rupture before 40
years old and in families with multiple cases of ICA or other
vascular events [19].
Computed tomography, magnetic resonance angiog-
raphy, and classical angiography are screening tests for
detection of intracranial aneurysms in ADPKD subjects at
high risk. The routine screening for asymptomatic ICA in
all ADPKD individuals is not indicated, but in families with
a proven case of ICA, a screening analysis is recommend in
consultation with a neurosurgeon.
3.Biomarkers
In general, biomarkers can be divided into 3 subtypes based
on the technical procedures used. Biomarkers measured by
laboratory tests are deﬁned as “laboratory or molecular
biomarkers”; those related to signaling, imaging, and func-
tional tests are deﬁned as “functional biomarkers”; those
related to genetic polymorphisms and other genomic tests
are deﬁned as “genetic biomarkers.”
3.1. Laboratory and Molecular Biomarkers
3.1.1. Renal Biomarkers. In patients with ADPKD, a limited
number of biomarkers have been investigated.
In a recent study, Meijer et al. investigated urinary
biomarkers for diﬀerent segments of the nephron in patients
with ADPKD versus healthy controls. They choose urinary
ImmunoglobulinG(IgG)asamarkerofglomerulardamage;
urinary β2-microglobulin (B2M), urinary kidney injury
molecule 1 (KIM-1), N-acetyl-β-D-glucosammide (NAG),
and neutrophil gelatinase-associated lipocalin (NGAL) as
markers for damage of the proximal tubule; urinary heart-
type fatty acid binding protein (HFABP) as a marker for
damage of the distal tubule. Urinary macrophage migration
inhibitory factor (MIF) and monocyte chemotatic protein 1
(MCP-1) were chosen as markers of inﬂammation.
Themostimportantﬁndingofthisstudyisthatexcretion
of all urinary biomarkers from all segments of the nephron
was increased in patients with ADPKD compared with
control subjects.
Furthermore, NGAL excretion was associated with renal
blood ﬂow and total renal volume independent of albumin-
uria.Inaddition,B2MandH-FABPwereassociatedinversely
with measured GFR and eﬀective renal blood ﬂow inde-
pendent of albuminuria; KIM-1, NGAL, and MCP-1 were
associated positively with total renal volume independent of
albuminuria [54].
In a recent paper, Bolignano et al. investigated and
reported urinary and serum NGAL levels in a sample of
26 ADPKD patients. They found that urinary and serum
NGAL levels were higher in ADPKD patients than in control
subjects. They found a strong correlation with the glomeru-
lar ﬁltration rate. In addiction, they divided patients into
two groups according to the cystic development and kidney
dimensions; subjects with higher cystic growth presented
higher urinary and serum NGAL values with respect to oth-
ers.TheyconcludedthathigherlevelsofNGALarecorrelated
to higher cystic growth and suggested that this protein could
be also involved in the process of cystogenesis [55].
In 92 patients with ADPKD, Casal et al. reported
a comparative study for three biomarker tests of early
kidney damage such as urinary albumin and total β-N-
acetylhexosaminidase (Hex) and its isoenzymes (Hex A,
Hex B), as well as serum glutathione peroxidase, which
h a sb e e nc o n s i d e r e da sam a r k e ro fr e n a lp r o x i m a lt u b u l a r
function. They found a frequent elevation of the urinary
Hex and an alteration of its isoenzymatic proﬁle, with
31% of the normotensive ADPKD subjects with normoal-
buminuria already presenting an increased proportion of
Hex B isoenzyme. Furthermore, keeping age constant,
they reported a partial signiﬁcant correlation between the
ultrasound score (kidney size and number of cysts) and
the proportion of Hex B, but not with albuminuria or
cystatin C. This conﬁrms the hypothesis that tubular damage
plays a role in the pathogenesis and progression of ADPDK
[56].
Wong et al. valued measure GFR and serum cystatin C
(Cys C) levels in 18 children with ADPKD versus 41children
with minor renal pathological states.
Serum creatinine levels did not diﬀer between the
ADPKDandcontrolgroup,butGFRwassigniﬁcantlygreater
in the ADPKD group than in controls. Cys C level for the
ADPKD group was signiﬁcantly lower than that of controls.
This study corroborates the increase of GFR in children
and adolescents with ADPKD and the superior diagnostic
performance of Cys C [57]. In fact, in patients with CKD,
Cys C was proposed to perform better as a marker of GFR
than serum creatinine [58].
Apart from being a good marker for renal function,
Cys C appears to be also a marker of cardiovascular risk in
CRS types 2 and 4 and oﬀers complementary prognostic
information to other cardiac biomarkers like troponin T and
NT-proBNP [58, 59]. High concentrations of circulating Cys
C have shown to be consistently and strongly associated with
the cardiovascular outcomes [60].International Journal of Nephrology 5
Another index of ADPKD progression is microalbu-
minuria; in fact, there are numerous reports that have
established that microalbuminuria is a frequent sign of
kidney impairment in the disease, associated with a major
cardiovascular risk. Microalbuminuria is present in patients
with chronic heart failure (CHF) and progressive renal
failure [46, 61]. In ADPKD patients, microalbuminuria is
associated with an increase in arterial pressure [61, 62]a n d
progression to renal failure [62], as well as with a more
severe cystic involvement [61]. Martinez-Vea et al. examined
the prevalence of microalbuminuria in a normotensive
ADPKD population. The study showed a high prevalence
of microalbuminuria in this group and a tendency of these
patients towards a greater systolic blood pressure, plasma
renin activity, and left ventricular mass [61]. There are few
information about renal alterations and vascular remodeling
in ADPKD patients with normal or minimally increased
levels of urine albumin excretion.
3.1.2. Cardiac Biomarkers. The natriuretic peptides (NPs)
are a well-described family of hormones with a major role
in sodium and body volume homeostasis [63]. BNP (brain
natriuretic peptide), and NT-proBNP are correlated with
the severity of heart failure (HF) and left ventricular (LV)
function and are useful markers for diagnosis, management,
andprognosisinpatientswithnormalrenalfunction.Recent
studies indicated that both BNP and troponin T have a
diagnostic power in patients with CKD to predict cardiovas-
cular disease [63, 64]. The NPs have shown prognostic utility
in patients with various stages of renal insuﬃciency [65],
demonstratingpotentialapplicationsinCRStypes2and4.It
is well established that patients with CKD have higher levels
ofbothBNPandNT-proBNPthanage-andgender-matched
subjects without reduced renal function, even in the absence
ofclinicalHF[66].Thus,therelationshipbetweenBNP,renal
function, and the severity of heart failure is less clear, and the
association between NPs levels and renal function remains
complex.
Cardiac troponin T (cTnT) is a speciﬁc marker
for myocardial damage and a myocardial infarction. In
hemodialysis patients, three large observational studies con-
cordant with cTnT levels are associated strongly with the
risk of incident for cardiovascular events [67–69]. Thus,
increased cTnT levels represent a strong and independent
predictor of global cardiovascular mortality in clinically
stable hemodialysis patients. However, there are few studies
describing the signiﬁcance and the prognostic value of
elevated serum cTnT levels in stable patients with moderate
CKD [70].
At this time, the relationship between renal function
and serum cTnT remains still unclear, and the signiﬁcance
of an increased cTnT concentration in patients with renal
dysfunction remains controversial [71].
Unfortunately, there are currently no published data
about speciﬁc cardiac biomarkers in ADPKD population.
3.2. Functional Biomarkers: Imaging Techniques (Table 2).
Imaging techniques may enhance, extend, and reﬁne our
ability to diagnose and follow up cardiac and renal diseases.
3.2.1. Imaging Techniques for ADPKD Diagnosis. The main
structural change seen for ADPKD is the formation of renal
cysts; thus, it is evident that any enlargement of the cysts
and the decrease in the volume of the renal parenchyma
are the key factors in the progress of this disease [41].
Diﬀerent imaging modalities such as Ultrasonography (US),
Computed Tomography (CT), and Magnetic Resonance
Imaging (MRI) have been used to quantify the size of the
kidney in ADPKD. The consortium for radiologic imaging
studies of polycystic kidney disease (CRISP) was created
to develop innovative imaging techniques and analyses to
follow disease progression or to evaluate treatments for
ADPKD.
Ultrasonography was the earliest method used to mea-
sure kidney volume in vivo and has the advantage of being
widely available and easily performed with modest cost
in comparison with CT scan and MRI. Unfortunately, US
cannot provide separate, reliable measurements of both the
renal cyst volume and the renal parenchymal volume [72].
Individuals who are at risk for ADPKD are often screened by
ultrasoundusingage-gradeddiagnostic criteria derivedfrom
individuals with mutations in PKD1 [73].
In families of unknown genotype, the presence of three
or more (unilateral or bilateral) renal cysts is suﬃcient for
establishing the diagnosis in individuals aged 15 to 39years;
twoormorecystsineachkidneyaresuﬃcientforindividuals
aged 40 to 59years, and four or more cysts in each kidney are
required for older individuals aged 60years. Conversely, less
than two renal cysts in at-risk individuals aged ≥40years are
suﬃcienttoexcludethedisease.USimagingdoesnotprovide
as u ﬃciently certain diagnosis in at-risk individuals younger
than30yearsofage;sotheutilityofthistechniquefordisease
exclusion is limited in younger subjects.
Families with mutations in PKD2 typically have less
severedisease;inADPKD2,themildrenalcysticinvolvement
has an adverse impact on the sensitivity of US criteria that
apply to diagnose the disease. As a result of reduced test
sensitivity, the diagnostic criteria in use have a suboptimal
performance for individuals with mutations in PKD2 [73].
For younger individuals in whom US might yield
equivocal or indeterminate results, a negative CT scan or
MRI may provide further assurance that they are unaﬀected.
CT scan and MRI have greater sensitivity so that smaller
cysts (∼2mm compared with ∼10mm for ultrasonography)
can be detected [74]. Both CT and MRI avoid the potential
pitfalls of US, that is, any operator-dependent techniques
or the need for multiple image acquisitions of large kid-
neys. Contrast media-enhanced CT or electron beam CT
techniques can provide accurate measurements not only of
the total kidney volume, but also of the renal cyst volumes
in ADPKD patients [75]. However, CT has two signiﬁcant
limitations: the radiation exposure and the requirement
for administering intravenous contrast media. The contrast
media may be associated with a small chance of serious
allergic reactions and nephrotoxicity in patients with renal
insuﬃciency.
MRI has increasingly been used because it provides high-
resolution 3D images with excellent tissue contrast without
exposure to ionizing radiation or iodinated contrastmedium6 International Journal of Nephrology
Table 2: Imaging techniques.
ADPKD diagnosis
Ultrasonography (US) Easy, available, and cheap method
Limited utility for disease exclusion in younger subjects
and suboptimal performance for individuals with
ADPKD type II
Computed tomography (CT) scan Detect small cysts (∼2mm)
Exposure to radiation and administration of
intravenous contrast media
Magnetic resonance imaging (MRI) Provide high-resolution 3D images
No exposure to radiation, no administration of
intravenous contrast media
Diagnosis of cardiovascular
complications
Echocardiography
Determine LV/RV size and function, LV wall motion
abnormalities, valvular function and abnormalities,
diastolic function, and presence or absence of
pericardial abnormalities or intracardiac masses
Transmitral pulsed doppler
Noninvasive method to evaluate the diastolic
dysfunction
Inﬂuenced the loading condition of the left atria and
heart rate.
Tissue doppler imaging (TDI) Permit an assessment of myocardial motion, a sensitive
index of ventricular relaxation
Cardiovascular magnetic resonance
imaging (cMRI)
Noninvasive test
Gold standard for the assessment of ventricular
dimensions.
[76]. While MRI is a reliable and precise method to measure
renal volume, little information and data are available in the
medical literature about the validity and accuracy of MRI-
based kidney volume measurements in ADPKD patients
[41, 76]. Initial preliminary reports from the CRISP indicate
that MRI is as least as accurate as CT scan for determining
the rate of increase in kidney volume [41]. At the present
time, MRI appears not appropriate for routine application.
SomeofthelimitationsofMRIincluderelativelylongimage-
acquisition times and variability in the quality of images that
can be produced from diﬀerent MR scanners [76].
3.2.2. Imaging Techniques for Diagnosis of Cardiovascular
Complications. Echocardiography determines left/right ven-
tricular size and function, left ventricular wall motion
abnormalities, valvular function and abnormalities, diastolic
function, and presence or absence of pericardial abnormal-
ities or intracardiac masses; it also evaluates intracardiac
ﬁlling pressures.
Transmitral pulsed doppler is the classical noninvasive
methodofevaluationofdiastolicdysfunction;itisinﬂuenced
by a variety of factors such as the loading condition of the
left atria and heart rate. Tissue doppler imaging (TDI) is
a new technique that permits an assessment of myocardial
motion, a sensitive index of ventricular relaxation, which
is more independent of the hemodynamic condition and,
therefore, a more reliable diastolic function index [77].
Unlike transmitral pulsed doppler, TDI directly measures
the mechanical wall function by calculating the velocity
of myocardial movement and has been shown to better
monitoring diastolic function of the myocardium.
Starting as a research method little more than a decade
ago, cardiovascular magnetic resonance imaging (cMRI) has
rapidly evolved to become a powerful diagnostic tool used
in routine clinical cardiology. CMRI provides a relatively
novel method for accurate deﬁnition of cardiac dimensions
and is accepted as the “gold standard” for the assessment of
ventricular dimensions. Beneﬁts of cMRI include the ability
to obtain a great deal of information with one noninvasive
test. CMRI is used for the assessment of regional and global
ventricular function and to answer questions regarding
anatomy.CMRIisabletoassessischemicversusnonischemic
disease,inﬁltrativedisease,valvularandcongenitaldisorders,
and hypertrophic disease, and determine viability. Unfortu-
nately, there are currently no published data using cMRI in
ADPKD patients.
3.3.GeneticBiomarkers. Genetictestsarethe“goldstandard”
to screen individuals for ADPKD. Molecular genetic tests are
helpful when imaging results are equivocal and/or when a
deﬁnite diagnosis is required in a younger adult. There are
2 methods for ADPKD DNA testing: linkage analysis and
direct mutation screening.
Presymptomatic testing is possible in larger families
by linkage analysis using highly informative microsatellite
markers ﬂanking the PKD1 and PKD2 genes. A signiﬁcant
limit of linkage analysis is the need for a relatively large
number of aﬀected family members in order to establish
the gene involved in the disease. In linkage analysis, the
segregation of chromosomal markers is examined and
compared within a family in whom the clinical status
(aﬀected or unaﬀected) of each individual is known. ByInternational Journal of Nephrology 7
examiningseveralmarkers,a“haplotype”(apatternofalleles
on the same chromosome that are inherited together) that
segregates with the disease can be determined [78]. There
are several limitations to linkage testing; the most important
is that no information can be obtained from testing the
probandalone.Furthermore,linkageanalysiscannotbeused
if a family is small, if family members refuseto participate, or
if the proband is suspected to have a de novo mutation.
A direct mutation analysis is another method for molec-
ular diagnosis in ADPKD. As ADPKD displays a high level of
allelic heterogeneity, the complete screening of both genes is
required.Mostmutationsareprivate(uniquetoasinglefam-
ily) and scattered throughout these genes with no clear “hot
spots.” Therefore, exon-by-exon screening of these genes is
required to ensure a high sensitivity in detecting disease-
causing mutations, thus screening approaches are expensive.
Screening of individuals with ADPKD detects mutations in
up to 91% of cases. However, only approximately 65% of
patients have deﬁnite mutations with approximately 26%
having nondeﬁnite changes that require further evaluation
[74]. ADPKD database (Autosomal Dominant Polycystic
Kidney Disease: Mutation Database) collects every known
variants on PKD1 and PKD2 to improve the diagnostic value
of molecular screening.
Furthermore, the recent availability of clinical molecular
genetic testing means such testing may be applied to asymp-
tomatic at-risk relatives of subjects with ADPKD. As with
most renal diseases, early diagnosis with implementation of
eﬀective interventions has important implications and the
best chance for preventing or slowing renal progression and
cardiac complications in patients with the ADPKD [79].
For example, the early intervention of diagnosing and
aggressively treating blood pressure in these patients, par-
ticularly blockade of the renin-angiotensin system, has the
potential of preventing LVH, cardiovascular complications,
and mortality [79].
In that regard, Schrier et al. have reported that the age of
ESRDinbothmenandwomenwithADPKDhasincreasedin
recent years and speculate that this eﬀect has been associated
with better blood pressure control and increased therapy
with ACE inhibitors [80].
Other relevant indications for early identiﬁcation of
ADPKD include the provision of more detailed and speciﬁc
information regarding prognosis and risk for complications,
the ability to make more informed reproductive choices,
motivation for enhanced compliance and medical followup,
and the evaluation of living donors form aﬀected families
[81]. Screening is also important in clearing prospective
living kidney donors from aﬀected families [81]. Screening
children under 18years old is not strongly recommended
because of the potential emotional and social impact of a
positive diagnosis in these younger subjects. Before screen-
ing, counselling from experienced staﬀ must be performed,
in order to facilitate appropriate life-style decisions.
4. Prevention,Management, and Trials
The core of the prevention is that the reduction in the
rate of progression of CKD may lead to a reduction of
the incidence of chronic renocardiac syndrome. Many novel
therapies have been evaluated in the cardiorenal syndrome
setting, including agents that may block key local factors
(e.g., adenosine A(I) receptor antagonists), improve diuresis,
aquaresis, and natriuresis, and augment natural vasodilator
mechanisms to improve renal perfusion [82].
There are no disease-speciﬁc therapies for any form of
ADPKD, and no evidence-based guidelines on the manage-
ment of ADPKD have been reported perhaps due to the
veryslowrateofdiseaseprogression.Interventionsshouldbe
capable to slow down, stop, or reverse structural progression
of the disease and should be able to prevent the decline
of renal function improving clinical outcome. In ADPKD,
only blood pressure control has been shown to have a
favorable impact on disease progression and cardiovascular
complication rate [83]. Rigorous control of blood pressure
may prevent progression of renal disease and decreases
the risk of cardiovascular morbidity that characterizes all
patients with CKD. The KDOQI Clinical Practice guidelines
on hypertension indicate that goal blood pressure should
be less than 130/80mmHg [84]. If there are no contraindi-
cations, an angiotensin-converting enzyme (ACE) inhibitor
should be the initial antihypertensive agent. Increased renin-
angiotensin system activity and extracellular volume expan-
sion play an important role in the pathogenesis of HP
in patients with ADPKD, thus patients generally respond
well to these agents [85]. ACE inhibitors or angiotensin
receptorblockers(ARBs)mayhaverenoprotectiveproperties
increasingrenalbloodﬂowwhichcorrelateswithprogression
of ADPKD and contributes to cyst growth [12, 47, 86]. In a
meta-analysis of 11 randomized controlled trials, Jafar et al.
found that ACE inhibitors were more eﬀective in lowering
urine protein excretion in patients with ADPKD compared
to regimes without ACE inhibitors, and it was more evident
in patients with higher levels of proteinuria. However, the
beneﬁt of ACE inhibitors on ADPKD progression remains
inconclusive [86].
Whether salt restriction and ACE inhibitors and ARBs
therapy fail to lower blood pressure suﬃciently, it may be
necessarytoaddadiuretic(thiazidesinitially,withaswitchto
loop diuretics if thiazides are not eﬀective) [25]. Additional
agents may then be added to gain an appropriate blood
pressure control and ameliorate other clinical advantages,
such as angina using a β-blockers or calcium channel block-
ers. Addition of β-blockers to ACE inhibitor/ARB therapy
is a very attractive choice, with documented cardiovascular
protective characteristics. Several studies have shown better
preservation of renal function or reduction in proteinuria
and LVH with ACE inhibitors or ARBs compared to diuretics
or calcium channel blockers [87, 88].
A controlled trial, the Halt Progression of Polycystic Kid-
ney Disease study (NCT00283686), funded by the National
Institutes of Health, is under way to determine whether
treatment with ACE inhibitors and ARBs, administered
singly or in combination, will reduce the rate of increase in
kidney volume and slow the decline in GFR [25]. Signiﬁcant
advances in terms to understand the genetics of ADPKD and
molecular mechanisms responsible for cyst initiation have
revealed likely targets for therapeutic intervention.8 International Journal of Nephrology
Table 3: Clinical trials for ADPKD.
Start-ﬁnish
date Intervention Action Design
HALT-ADPKD STUDY
(NCT00283686) 2006–2013 ACE inhibitors and ARBs
(singly or in combination)
Reduce the rate of
increase in kidney
volume and slow the
decline in GFR
Multicenter, randomized,
placebo controlled
NCT00428948 2007–2011 V2 receptor antagonist
(Tolvaptan)
Reduce the
concentrations of cAMP
and slow the progression
of renal enlargement
Multicenter, double blind,
placebo controlled
NCT00309283 2006–2010 Long-acting somatostatin
(octreotide)
Inhibit the growth of the
polycystic kidneys and
liver
Randomized Single Center,
Single blind, Placebo
controlled
NCT00426153
2007–2010
(open-label
extention)
Long-acting somatostatin
(octreotide)
Inhibit the growth of the
polycystic kidneys and
liver
Double blind, Randomized,
Placebo controlled,
Crossover
NCT00565097
2007–2009
(open-label
extention)
Long-acting somatostatin
(lanreotide)
Inhibit the growth of the
polycystic kidneys and
liver
Double blind, Randomized,
Placebo controlled
Trials with target
mTOR — mTOR inhibitors
(sirolimus, everolimus)
Modulate disease
progression and
development of renal
cysts
—
At the present time, there are no therapies proving a cyst
progression delay and their complications, and there is no
proven antihypertensive drug of choice neither in ADPKD
patients nor in ADPKD patients on dialysis. An eﬀective
control of HP remains one of the few modiﬁable factors
by medical intervention and may delay the development of
LVH, which is strongly related with diastolic dysfunction
[21]. A better understanding of the pathophysiology and the
availability of animal models has enabled the development
of preclinical trials and the identiﬁcation of promising
candidate drugs for clinical trials [12].
An hopeful therapeutic strategy, to inhibit cyst develop-
ment in ADPKD, is modulating cyclic AMP (cAMP) levels.
Arginine vasopressin (AVP) is a potent activator of renal
adenyl cyclase [25]. The eﬀect of AVP, via V2 Receptors,
on cAMP levels in the collecting duct and distal nephron
and the role of cAMP in cystogenesis provided the rationale
for preclinical trials of vasopressin V2 receptor (VPV2R)
antagonists [89]. In particular, one of these drugs, OPC-
31260, reduces the concentrations of cAMP and inhibits
cyst development in animal models of ADPKD [90]. An
antagonist with high potency and selectivity for the human
VPV2R (tolvaptan) has also been shown to be an eﬀective
treatment in PKD2 mouse model of autosomal dominant
polycystic kidney disease [91]. The usefulness of AVP-V2
inhibitors in slowing the progression of renal enlargement
and insuﬃciency in patients with ADPKD is currently
evaluating in a placebo-controlled trial (NCT00428948)
[25]. Small clinical trials (NCT00309283, NCT00426153,
and NCT00565097) have shown that the administration of
octreotide or lanreotide for a period of 6 to 12 months
inhibits the growth of polycystic kidneys and livers [92–94].
Another promising therapeutic strategy might involve
inhibitors of mTOR. The absence of polycystin permits
excessive kinase activity in the mammalian which is the
target of rapamycin (mTOR) pathway and the development
of renal cysts [26]. The mTOR system can be blocked by
rapamycin (sirolimus, everolimus), so it may be another
possible strategy to modulate disease progression in ADPKD
patients. Wahl et al. [95] found that inhibition of mTOR
with rapamycin slows ADPKD progression and kidney
enlargement in rats. In a prospective study in humans,
rapamycin reduced polycystic liver volumes in ADPKD renal
transplant recipients [96]. Larger studies of longer duration
are needed to conﬁrm the safety and to sustain eﬃcacy of
these novel treatments.
Experimental and clinical studies have suggested that
statins may slow the progression of chronic kidney disease in
general and ADPKD speciﬁcally [97]. Statins are widely used
to lower cholesterol, and they have anti-inﬂammatory and
antiproliferative qualities. However, there are some reported
animal studies in Han:SPRD rats, an ADPKD model with
many of the characteristics of the disease in humans, that
demonstrate that statins reduce cyst formation and improve
renal function [98].
Moreover, Namli et al. have shown in patients with
ADPKD that statins have a beneﬁcial eﬀect in the reversal of
endothelial dysfunction, an early manifestation of vascular
injury. Six months of simvastatin therapy resulted in a sig-
niﬁcant improvement of endothelial dysfunction in patients
with ADPKD. This ﬁnding may be in part related to the
pleiotropic eﬀects of simvastatin [99].
A clinical trail is currently in progress at the Uni-
versity of Colorado regarding ADPKD and pravastatinInternational Journal of Nephrology 9
(NCT00456365) [100]. This study is designed to determine
if the treatment with pravastatin can slow the progression
of kidney and heart disease when initiated early in life in
patients with ADPKD. This trial is expected to complete
enrollment in 2011. The endpoints of interest in this three-
year study include total kidney volume and LVH index as
measured MRI; urinary albumin excretion and endothelial-
dependent vasodilation as assessed by brachial ultrasound
[100]( Table 3).
In conclusion, recent studies using diﬀerent animal
models of renal cystic diseases have suggested that various
pharmacological interventions may modify disease progres-
sion. This clearly demonstrates that a better comprehension
of the molecular and cellular defects underlying cystogenesis
may lead to design novel therapeutic agents or a better use
of existing ones. It is therefore likely that trials in human
ADPKD will be carried out in the near future, especially
as methods for assessing disease progression in the short
term are now available [41, 101]. Other important thing
is that genetic counseling to discuss genetic risk, screening,
and prenatal and predictive testing should be oﬀered to all
individuals with or at risk of inheriting ADPKD.
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